Bayer's Bull Case Rests on Guidance, Not on Beating the Numbers

Two brokerage notes landed on Bayer this week with identical verdicts and different reasoning — and neither is built on the expectation of a blowout quarter. JPMorgan kept its "Overweight" rating on Wednesday with a price target of 61 euros, while UBS reaffirmed its buy recommendation on Thursday at 62 euros. What separates the two is where each firm thinks the reassurance will come from.

At JPMorgan, analyst Richard Vosser is modelling revenue 2% above consensus, yet his EBITDA estimate sits 6% below the average market forecast. That divergence matters more than the headline rating: stronger sales in his model do not translate into a stronger operating result than the market anticipates. The positive call survives that earnings gap, and Vosser points to the expected confirmation of full-year guidance as the likely anchor for confidence — not a fresh positive impulse from the company itself.

Two Houses, Two Anchors

UBS takes a different route to the same conclusion. Analyst Matthew Weston acknowledged the well-known weakness in the agricultural business but argued that trends for 2026 and 2027 should remain intact, with momentum in the pharmaceutical division likely to have carried through. That, too, is a forecast made ahead of the figures rather than a reported outcome.

The distinction is worth spelling out. JPMorgan emphasises the signalling value of the annual outlook; UBS leans on the expected durability of business trends despite the softness in agriculture. Neither view rests on the agricultural drag having already been overcome.

Pipeline News Cuts Both Ways

Supporting the pharma side of the argument is a pair of recent announcements, though each sits at a different stage of the long road to commercial reward. Roughly a week ago, the FDA accepted Bayer's supplemental application for Finerenon — marketed as Kerendia — covering chronic kidney disease without diabetes, based on positive results from the Phase III FIND-CKD trial. Acceptance is a regulatory milestone, not an approval of the requested use.

Separately, Bayer subsidiary Vividion began a global Phase II study of VVD-214 in combination with pembrolizumab, dosing its first patient. The trial enrols previously untreated patients with advanced MSI-H or dMMR colorectal cancer. Vividion is wholly owned by Bayer but operates independently. Starting a study extends the clinical development of the compound; it does not establish efficacy from that trial, nor does it amount to an authorisation.

Both items bolster the case for the pharma franchise without yet demonstrating a resulting business success — a nuance that matters when reading the bullish notes.

The November Reckoning

The next hard checkpoint is Bayer's quarterly statement for the third quarter of 2026, scheduled for 3 November. That release offers the first concrete opportunity to test the optimistic pharma narrative and the acknowledged farm weakness against actual operating performance. Guidance confirmation remains an analyst expectation at this point, not a decision Bayer has announced.

Lurking in the background is the unresolved glyphosate settlement, which media reports continue to flag as a source of uncertainty. Neither buy rating removes that risk. For investors, the takeaway is a clean split: the recommendations rest on anticipated business trends and confidence in the forecast, and they are no proof that the operating and legal burdens have already been left behind.